Literature DB >> 11740146

Cardiac performance in Turner's syndrome patients on growth hormone therapy.

G Radetti1, R Crepaz, O Milanesi, C Paganini, A Cesaro, F Rigon, W Pitscheider.   

Abstract

OBJECTIVES: To investigate possible cardiac morphofunctional alterations observed in 26 Turner's syndrome (TS) patients on prolonged high-dose growth hormone (GH) therapy. STUDY
DESIGN: We examined 26 TS subjects treated with rhGH (1 U/kg/week) for a mean period of 4.9 years (range 1-7.8) and 37 age-, weight- and height-matched healthy girls. Left ventricular volume, mass, systolic function, cardiac index, systemic vascular resistance and diastolic function were evaluated by two-dimensional and Doppler echocardiography.
RESULTS: Heart rate and systolic blood pressure (BP) were higher in TS patients than in controls, while diastolic BP was lower. Left ventricular volumes, ejection fraction, mass index, M/V ratio and cardiac index did not differ significantly; systemic vascular resistance was slightly decreased. Left ventricular fractional shortening and mean velocity of circumferential shortening were slightly increased while end-systolic meridional stress was decreased in TS. Contractile state was normal in TS. Diastolic function assessment showed a shortening of isovolumetric relaxation and diastolic filling times with an increased atrial contribution and a normal pulmonary venous flow.
CONCLUSION: Cardiac morphology in TS patients on GH therapy is similar to controls. The observed changes in left ventricular systolic and diastolic function should be interpreted as an adaptation to the higher heart rate and reduced peripheral vascular resistance induced by GH therapy. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740146     DOI: 10.1159/000050003

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  5 in total

1.  Evaluation of function and structure of arterial wall in girls and young women with Turner syndrome.

Authors:  G Radetti; L Mazzanti; C Di Somma; M Salerno; E Gottardi; D Capalbo; F Tamburrino; A Colao
Journal:  J Endocrinol Invest       Date:  2015-04-02       Impact factor: 4.256

2.  Growth hormone treatment and left ventricular dimensions in Turner syndrome.

Authors:  Lea Ann Matura; Vandana Sachdev; Vladimir K Bakalov; Douglas R Rosing; Carolyn A Bondy
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

3.  Recombinant human growth hormone in the treatment of Turner syndrome.

Authors:  Bessie E Spiliotis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 4.  Pheochromocytoma as a rare cause of hypertension in a 46 X, i(X)(q10) turner syndrome: a case report and literature review.

Authors:  Ji Yeon Shin; Bo Hyun Kim; Young Keum Kim; Tae Hwa Kim; Eun Heui Kim; Min Jin Lee; Jong Ho Kim; Yun Kyung Jeon; Sang Soo Kim; In Joo Kim
Journal:  BMC Endocr Disord       Date:  2018-05-10       Impact factor: 2.763

5.  The Usefulness of Magnetic Resonance Imaging of the Cardiovascular System in the Diagnostic Work-Up of Patients With Turner Syndrome.

Authors:  Monika Obara-Moszynska; Justyna Rajewska-Tabor; Szymon Rozmiarek; Katarzyna Karmelita-Katulska; Anna Kociemba; Barbara Rabska-Pietrzak; Magdalena Janus; Andrzej Siniawski; Bartlomiej Mrozinski; Agnieszka Graczyk-Szuster; Marek Niedziela; Malgorzata Pyda
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-16       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.